Get notified when TRAW files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTraws Pharma launches antiviral program targeting Hantavirus and Ebola outbreaks
Filed May 27, 2026 · Period ending May 27, 2026 · ~1 min read
Key Changes
-
medium
Company announced new antiviral program focused on ongoing Hantavirus and Ebola Virus disease outbreaks, representing expansion into new therapeutic areas beyond existing pipeline.
Item 7.01 verify on EDGAR → -
low
Disclosure made via press release under Regulation FD requirements, indicating company is providing material information to all investors simultaneously.
8-K: Press Release verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ADMT 10-K) is open in full — no account needed.
Partner
Trade TRAW commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · May 27, 2026 · How we verify